ADMA Biologics (NASDAQ:ADMA) Trading 3.5% Higher

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price traded up 3.5% during trading on Tuesday . The company traded as high as $6.19 and last traded at $6.19. 862,242 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 2,645,077 shares. The stock had previously closed at $5.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Mizuho lifted their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald lifted their target price on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.88.

ADMA Biologics Stock Performance

The company’s 50 day moving average price is $5.91 and its two-hundred day moving average price is $4.73. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The business had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.3 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms sold 407,000 shares of ADMA Biologics stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the transaction, the director now owns 3,208,671 shares in the company, valued at approximately $19,925,846.91. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is owned by corporate insiders.

Institutional Trading of ADMA Biologics

Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP increased its holdings in shares of ADMA Biologics by 87.7% in the 3rd quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock worth $867,000 after buying an additional 113,184 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in ADMA Biologics by 22.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after purchasing an additional 224,696 shares during the last quarter. American Century Companies Inc. grew its holdings in ADMA Biologics by 20.8% during the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after purchasing an additional 840,761 shares during the last quarter. Aigen Investment Management LP bought a new position in ADMA Biologics during the 3rd quarter valued at about $140,000. Finally, SG Americas Securities LLC grew its holdings in ADMA Biologics by 417.3% during the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 75,213 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.